ARVN

Arvinas, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/05/2026

Business Summary

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

 


Analyze ARVN on TradingView

VALUATION

P/E

-2.56

Market Cap ($M USD)

$570.37M

Forward P/E

-4.99

PEG

-0.10

PRICE TO SALES

6.38

PRICE TO BOOK

1.46

EV / EBITDA

-2.12

5-Year Average P/E

Free Cash Flow Yield

-45.04%

DCF Value

$-125.66

Graham Number

N/A

Price to FCF

-2.22

EV to FCF

-1.91

Earnings Yield

-39.12%

FCF Yield

-45.04%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.46

Next Year EPS Growth Estimate

-$1.77

Next Year Revenue Growth Estimate

$16.04B

Return on Equity (ROE)

-44.39%

FREE CASH FLOW

Operating Margin

-279.31%

Debt-to-Equity

0.02

Piotroski F-Score

3

Altman Z-Score

-2.37

Return on Invested Capital (ROIC)

-46.97%

Current Ratio

5.44

Quick Ratio

5.44

Net Debt to EBITDA

0.34

Interest Coverage

0.00

Gross Profit margin

97.43%

FCF PER SHARE

$-4.01

REVENUE PER SHARE

$1.40

Analyze ARVN on TradingView

Gainseekers Quantitative Analysis

Summary

Arvinas, Inc. is trading in a precarious zone, with its market valuation starkly misaligned with its DCF value. The Forward P/E of -7.10 and a negative Earnings Yield indicate a company struggling to translate its operations into profitability. The Altman Z-score of -0.95 signals financial distress, suggesting potential bankruptcy risk. Despite a consensus “Buy” rating, these metrics paint a picture of a company that is not only overvalued but also financially vulnerable, raising red flags for cautious investors.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Arvinas is well-positioned to leverage AI advancements for drug discovery and development. The industry's inherent focus on innovation aligns with technological shifts, potentially enhancing efficiency and reducing time-to-market. However, the company's ability to capitalize on these opportunities depends heavily on its strategic execution and investment in R&D.

The Bull Case

For the value-driven investor, Arvinas presents an intriguing opportunity. The low Debt/Equity ratio of 0.02 and a strong Current Ratio of 4.92 suggest robust liquidity and financial prudence. Despite a negative ROIC of -20.09%, the company's high Gross Profit Margin of 99.54% indicates significant pricing power. These factors, coupled with a Piotroski F-Score of 4, suggest operational resilience and potential for long-term capital efficiency.

The Bear Case

The bear case for Arvinas is compelling, with structural weaknesses evident in its financial metrics. The negative EV to EBITDA of -5.26 and Price to FCF of -2.35 highlight severe cash flow issues. Trading at a Price/Book of 1.51 and Price/Sales of 2.46, the stock appears overvalued relative to its fundamentals. Additionally, the stock's proximity to its 52-week high suggests technical overextension, making it a risky bet for conservative investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$14.75

Institutional Ownership %

1-Year Beta

1.80

Insider Buying % (6 Mo)

Distance to 52-Week High

64.14%

Distance to 52-Week Low

31.45%

EARNINGS SURPRISE %

5.26%

50-DAY SMA

$10.26

200-DAY SMA

$10.64

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.